Wei Li

TL;DR: Among patients with HER2‐negative metastatic breast cancer and a germline BRCA mutation, Olaparib monotherapy provided a significant benefit over standard therapy; median progression‐free survival was 2.8 months longer and the risk of disease progression or death was 42% lower with olaparIB monotherapy than with standard therapy.

TL;DR: Afatinib significantly improves progression-free survival with a tolerable and manageable safety profile in Asian patients with EGFR mutation-positive advanced lung NSCLC and should be considered as a first-line treatment option for this patient population.

TL;DR: Results suggest that hyperglycemia directly induces apoptotic cell death in the myocardium in vivo, mediated, at least in part, by activation of the cytochrome c-activated caspase-3 pathway, which may be triggered by ROS derived from high levels of glucose.

TL;DR: In this paper, an open-label, phase 3 randomised controlled trial at 183 cancer centres in 23 countries worldwide was conducted to compare erlotinib (a reversible EGFR tyrosine kinase inhibitor) with afatinib (40 mg per day) until disease progression.

TL;DR: Data suggest that FECR1 circular RNA acts as an upstream regulator to control breast cancer tumor growth by coordinating the regulation of DNA methylating and demethylating enzymes.